Table 2.
Description study population stratified by vital status at t2.
| Variable | Value | Alive at time of censoring N = 976 (88.6%) N (row%)/ mean (SD) | Deceased at t2 N = 126 (11.4%) N (row%)/ mean (SD) | All responder N = 1102 N (column%)/ mean (SD) |
|---|---|---|---|---|
| Sex* | Female | 489 (91.1%) | 48 (8.9%) | 537 (48.7%) |
| Male | 487 (86.2%) | 78 (13.8%) | 565 (51.3%) | |
| Age at baseline | 56.4 (15.9) | 58.2 (16.1) | 56.2 (15.9) | |
| Employment status at baseline* | Employed/ self employed | 443 (91.3%) | 42 (8.7%) | 485 (44%) |
| Unemployed | 40 (87%) | 6 (13%) | 46 (4.2%) | |
| Disability pension | 109 (79.6%) | 28 (20.4%) | 137 (12.4%) | |
| Early retirement/ retirement pension/ partial retirement | 334 (88.1%) | 45 (11.9%) | 379 (34.4%) | |
| Housewife/ houseman | 25 (96.2%) | 1 (3.8%) | 26 (2.4%) | |
| School/ apprenticeship/ study | 15 (88.2%) | 2 (11.8%) | 17 (1.5%) | |
| Unknown | 10 (83.3%) | 2 (16.7%) | 12 (1.1%) | |
| Education (school) | None to secondary school (8/ 9 years) | 229 (86.7%) | 35 (13.3%) | 264 (24%) |
| Secondary school (10 years) | 329 (87.7%) | 46 (12.3%) | 375 (34%) | |
| Vocational baccalaureate | 112 (94.9%) | 6 (5.1%) | 118 (10.7%) | |
| High school/ baccalaureate | 281 (88.6%) | 36 (11.4%) | 317 (28.8%) | |
| Something else/ unknown | 25 (89.3%) | 3 (10.7%) | 28 (2.5%) | |
| Sarcoma type—generala | Soft tissue sarcoma | 674 /87.0) | 101 (13.0) | 775 (70,3) |
| Bone sarcoma | 178 (90.4) | 19 (9.6) | 197 (17.9) | |
| GIST | 124 (12.7) | 6 (4.8) | 130 (11.8) | |
| Sarcoma type*** | Unclassified sarcoma | 136 (83.4%) | 27 (16.6%) | 163 (14.8%) |
| Fibroblastic, myofibroblastic, fibrohistiocytic | 119 (93%) | 9 (7%) | 128 (11.6%) | |
| GIST | 124 (95.4%) | 6 (4.6%) | 130 (11.8%) | |
| Liposarcoma | 192 (91.9%) | 17 (8.1%) | 209 (19%) | |
| Leiomyosarcoma | 117 (88.6%) | 15 (11.4%) | 132 (12%) | |
| Osteosarcoma | 64 (90.1%) | 7 (9.9%) | 71 (6.4%) | |
| Synovialsarcoma | 39 (81.3%) | 9 (18.8%) | 48 (4.4%) | |
| Ewing sarcoma | 42 (93.3%) | 3 (6.7%) | 45 (4.1%) | |
| Chondrosarcoma | 55 (85.9%) | 9 (14.1%) | 64 (5.8%) | |
| Others | 88 (78.6%) | 24 (21.4%) | 112 (10.2%) | |
| Site* | Abdomen/ retroperitoneum | 270 (90.3%) | 29 (9.7%) | 299 (27.1%) |
| Thorax | 75 (83.3%) | 15 (16.7%) | 90 (8.2%) | |
| Pelvis | 105 (85.4%) | 18 (14.6%) | 123 (11.2%) | |
| Lower limbs | 365 (91.3%) | 35 (8.8%) | 400 (36.3%) | |
| Upper limbs | 72 (85.7%) | 12 (14.3%) | 84 (7.6%) | |
| Head and neck | 26 (74.3%) | 9 (25.7%) | 35 (3.2%) | |
| Spine (bone spine and pelvis) | 38 (88.4%) | 5 (11.6%) | 43 (3.9%) | |
| Unknown/other | 25 (89.3%) | 3 (10.7%) | 28 (2.5%) | |
| T-stage at diagnosis | Small T1 | 158 (91.9%) | 14 (8.1%) | 172 (15.6%) |
| Large (T2–T4) | 459 (89.6%) | 53 (10.4%) | 512 (46.5%) | |
| Other/ unknown | 359 (85.9%) | 59 (14.1%) | 418 (37.9%) | |
| Grading at diagnosis* | Low grade | 129 (95.6%) | 6 (4.4%) | 135 (12.3%) |
| High grade | 524 (87.2%) | 77 (12.8%) | 601 (54.5%) | |
| Not applicable/ unknown | 323 (88.3%) | 43 (11.7%) | 366 (33.2%) | |
| Time since diagnosis (baseline)** | 0–<0.5 year | 178 (84.8%) | 32 (15.2%) | 210 (19.1%) |
| 0.5–<1 year | 100 (81.3%) | 23 (18.7%) | 123 (11.2%) | |
| 1–<2 years | 145 (87.9%) | 20 (12.1%) | 165 (15%) | |
| 2–<5 years | 269 (91.8%) | 24 (8.2%) | 293 (26.6%) | |
| More than 5 years | 284 (91.3%) | 27 (8.7%) | 311 (28.2%) | |
| Tumour recurrence until baseline** | No recurrence | 719 (90.4%) | 76 (9.6%) | 795 (72.1%) |
| Recurrence | 234 (83.9%) | 45 (16.1%) | 279 (25.3%) | |
| Suspicion/ unknown | 23 (82.1%) | 5 (17.9%) | 28 (2.5%) | |
| Metastasis until baseline*** | No metastasis | 579 (96.2%) | 23 (3.8%) | 602 (54.6%) |
| Metastasis | 253 (72.5%) | 96 (27.5%) | 349 (31.7%) | |
| Unknown/ suspicion | 144 (95.4%) | 7 (4.6%) | 151 (13.7%) | |
| Disease status at baseline*** | Complete remission | 482 (98.6%) | 7 (1.4%) | 489 (44.4%) |
| Partial remission + stable disease | 291 (88.4%) | 38 (11.6%) | 329 (29.9%) | |
| Tumour progress | 103 (64.4%) | 57 (35.6%) | 160 (14.5%) | |
| Unknown or not accessible | 100 (80.6%) | 24 (19.4%) | 124 (11.3%) | |
| Comorbidities** | None | 492 (91.1%) | 48 (8.9%) | 540 (49%) |
| 1 | 308 (85.6%) | 52 (14.4%) | 360 (32.7%) | |
| 2 | 135 (88.8%) | 17 (11.2%) | 152 (13.8%) | |
| 3 | 35 (89.7%) | 4 (10.3%) | 39 (3.5%) | |
| 4 and more | 6 (54.5%) | 5 (45.5%) | 11 (1%) | |
| Surgery until baseline*** | No | 100 (75.2%) | 33 (24.8%) | 133 (12.1%) |
| Yes | 876 (90.4%) | 93 (9.6%) | 969 (87.9%) | |
| Chemotherapy until baseline*** | No | 556 (95.9%) | 24 (4.1%) | 580 (52.6%) |
| Yes | 420 (80.5%) | 102 (19.5%) | 522 (47.4%) | |
| Radiotherapy until baseline | No | 601 (89.3%) | 72 (10.7%) | 673 (61.1%) |
| Yes | 375 (87.4%) | 54 (12.6%) | 429 (38.9%) | |
| Treatment intention***/a | Curative | 783 (95.5%) | 37 (4.5%) | 820 (74.4%) |
| Palliative | 175 (67.3%) | 85 (32.7%) | 260 (23.6%) | |
| Unknown | 18 (81.8%) | 4 (18.2%) | 22 (2%) |
N = 1102.
*p < 0.05.
**p < 0.01.
***p < 0.001 (chi square).
aNo model variable.